fosun pharma and mimivaxhave signed exclusive license for fosun pharma to diversify its product portfolio and to gain an innovated central nervous system oncology treatment
prevalent in the elderly, and more so among men than women, glioblastoma is an adult-common malignant neuroepithelial neoplasm in the central nervous system. as grade iv, the most devastating type in the world health organization’s (who) classification of central nervous system tumors, the tumor has a fast growth rate, with 70-80% of patients surviving a disease course of only 3 to 6 months. presently. glioblastoma is mainly treated with surgery, radiotherapy, chemotherapy and other supportive therapy, and its median survival time is in the range of 14.5 to 16.6 months.
mimivax llc is a ny based private, clinical-stage biotechnology company formed in 2011 to develop and commercialize its lead candidate survaxm, a pipeline immunotherapeutics for cancer and autoimmune diseases. survaxm is designed to stimulate the immune system to kill tumor cells that contain survivin, a cell-survival protein present in many cancers (glioma, multiple myeloma, net, medulloblastoma, melanoma, renal, breast and ovarian). survaxm triggers t-cell and b cell immunity simultaneously with unique cellular and antibody-mediated anti-tumor responses.
up to now, in the united states, this product has completed the phase i clinical safety studies for glioblastoma and phase ii clinical study of newly diagnosed glioblastoma, and has commenced the phase i clinical study of multiple myeloma and neuroendocrine tumors.
established in 1994, fosun pharma is a leading healthcare industrial group in china. this collaboration mainly focuses on tumor diseases including central nervous system tumors, which is complementary to the main therapeutic focus of fosun pharma. "we are pleased to partner with mimivax to bring such a promising immunotherapy to china," said wu yifang, fosun pharma’s president and ceo. “our collaboration with mimivax will enrich fosun pharma’s pipeline and provide one more therapy choices for unmet clinical demands on the market.”